SUNRRISE began its feasibility phase in December 2018, which aimed to recruit 70 patients over 6-months from at least 5 sites, and this was completed in May 2019. We will open the trial at a minimum of 25 sites overall and are pushing ahead with the second wave of setting up sites that have confirmed they wish to participate in the trial.
It is hoped that we will open at even more sites as there is a great deal of interest and enthusiasm for SUNRRISE. We still welcome completed Site Feasibility Assessment and Registration Form for further centres, who will be placed on a waiting list for the third wave of opening sites to the trial.
If you have any queries or would like to discuss participation as a site in the trial, please contact the SUNRRISE Trial Office.